Clin2
NCT07408505Possibly a fitRecruiting

New appetite drug for weight loss in advanced pancreatic cancer

Advanced Pancreatic Ductal AdenocarcinomaCancer Anorexia-Cachexia Syndrome

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests a new form of a drug (nano-megestrol acetate) to help people with advanced pancreatic cancer who are losing weight and have poor appetite. It aims to see if it can improve cachexia, a condition of severe weight loss and muscle wasting.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
56 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have advanced pancreatic cancer that has not been treated with chemotherapy for spread disease.
  • You have lost weight without trying or have a low body weight along with signs of inflammation.
  • You are between 18 and 75 years old and in reasonably good health (able to do daily activities).
  • You are not taking other drugs that boost appetite or weight, and you have no serious stomach or gut problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07092137Not yet recruiting· Phase 2
Nano megestrol for appetite and weight loss in advanced lung cancer

This trial tests a nano form of megestrol acetate, a drug that may help improve appetite and reduce weight loss in people with advanced lung cancer who have already lost weight or have signs of inflammation. It's for those who have not yet had chemotherapy for advanced disease.

NCT06909383Not yet recruiting· Phase 2
A drug for appetite and weight loss in advanced lung cancer

This trial tests a medicine called nanocrystalline megestrol acetate to help people with advanced small cell lung cancer who have lost weight and appetite. The goal is to see if the drug can improve their condition.

NCT07356037Not yet recruiting· Phase 3
Nanocrystalline megestrol acetate for liver cancer wasting

This trial tests a drug called nanocrystalline megestrol acetate to help people with advanced liver cancer who are losing weight and muscle mass. It's for those who have not yet had systemic therapy and are receiving other cancer treatments at the same time.

Chengdu, Sichuan
NCT06961201Not yet recruiting· Phase 3
Appetite medicine study for lung cancer with weight loss

This trial tests a new appetite-boosting medicine (nano-crystalline megestrol acetate) added to standard chemotherapy for people with advanced small cell lung cancer who are losing weight. It aims to see if it helps with weight, strength, and treatment response.

Chengdu, Sichuan
NCT06961188Not yet recruiting· Phase 3
Appetite and weight gain study for advanced lung cancer

This trial tests a new form of megestrol acetate (a medicine used to boost appetite and help with weight gain) in people with advanced lung cancer who are losing weight or at risk of weight loss. It aims to improve appetite and help you gain weight.

Wuhan, Hubei
NCT06940102Recruiting
A study on megestrol acetate for weight loss in advanced digestive cancer

This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).

Shenyang, Liaoning

Hear when a new Advanced Pancreatic Ductal Adenocarcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.